Table 1 Baseline characteristics of patients (n = 201)
| Â | Whole sample | Tretament-naive | Switchers for failure | Switchers for safety | Â |
|---|---|---|---|---|---|
N | 201 | 24 | 117 | 60 | Â |
Gender, n (%) | |||||
 Female | 141 (70) | 17 (71) | 88 (75) | 36 (60) |  |
 Male | 60 (30) | 7 (29) | 29 (25) | 24 (40) |  |
Age, years | |||||
 mean (SD) | 37.9 (9.3) | 37.2 (8.0) | 37.5 (9.9) | 39.0 (8.5) |  |
 median [range] | 38 [18–60] | 37 [20–53] | 38 [18–60] | 39 [18–60] |  |
Time since first symptom, years | * | ||||
 mean (SD) | 8.8 (6.0) | 5.1 (5.8) | 8.2 (5.8) | 11.3 (5.6) |  |
 median [range] | 8 [<1–23] | 2 [<1–18] | 11 [2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23] |  | |
EDSS score | Â | Â | Â | Â | * |
 mean (SD) | 2.7 (1.4) | 2.5 (1.0) | 2.4 (1.3) | 3.4 (1.5) |  |
 median [range] | 2.0 [0–6.5] | 2.0 [0–5.0] | 2.0 [1.0–5.5] | 3.5 [1.0–6.5] |  |
No. of relapses in previous year | * | ||||
 mean (SD) | 1.1 (0.6) | 1.3 (0.5) | 1.2 (0.4) | 0.9 (0.8) |  |
 median [range] | 1 [0–3] | 1 [0-3] |  | ||
Presence of gadolinium-enhancing lesions, n (%) | 125 (62) | 17 (71) | 78 (67) | 30 (50) | Â |